Drug
FT218
FT218 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)
Phase Distribution
Ph phase_3
3
100%
Phase Distribution
0
Early Stage
0
Mid Stage
3
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 33 (100.0%)
Trials by Status
completed267%
active_not_recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_3
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
NCT06525077
completedphase_3
An Open Label Study of FT218 in Subjects With Narcolepsy
NCT04451668
completedphase_3
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
NCT02720744
Clinical Trials (3)
Showing 3 of 3 trials
NCT06525077Phase 3
Safety and Efficacy of FT218 in Idiopathic Hypersomnia (REVITALYZ)
NCT04451668Phase 3
An Open Label Study of FT218 in Subjects With Narcolepsy
NCT02720744Phase 3
Once-Nightly Sodium Oxybate for Treatment of Excessive Daytime Sleepiness and Cataplexy in Narcolepsy
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3